← Back to Calendar

cendakimab

AbbVie / Arena Pharma · $ABBV
Priority Review Breakthrough Therapy NDA
PDUFA Date
June 8, 2026
Time Remaining
76 days
Review Type
Priority (6 mo)
90%
Baseline PoA
Historical NDA
approval rate
Dynamic PoA
Coming soon
xAI Sentiment

Indication

Eosinophilic esophagitis (EoE)

Key Notes

Oral IL-13 receptor inhibitor for EoE. First oral targeted therapy for this condition.
⚠️ Not Investment Advice: This information is provided for educational purposes only. PDUFA dates are FDA target action dates, not guaranteed approval dates. The FDA may extend the review period, issue Complete Response Letters, or take unexpected actions. Probability of approval scores are based on historical base rates and do not account for drug-specific factors. Always consult a financial advisor before making investment decisions.
← Back to Full Calendar
Advertisement